EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts

Mara Memoli, Stefania Leone, Vincenzo Fotticchia, Simona Avilia, Novella Pugliese, Catello Califano, Maria Di Perna, Danilo De Novellis, Antonella Malandrini, Bianca Serio, Camilla Frieri, Giuseppe Gaeta, Chiara Masucci, Alessandro D'Ambrosio, Paola Della Cioppa, Giuseppe Cerciello, Tiziana Izzo, Mario Annunziata, Annamaria Maddaloni, Cono Quagliano, Giorgia Battipaglia, Marco Picardi, Francesco Grimaldi, Fabrizio Pane

Hematological Oncology · 2026-11 · 44 (6)

DOI: 10.1002/hon.70281 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Long‐term real‐world data on Luspatercept (Luspa) in lower‐risk myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and transfusion‐dependent anemia (RBC‐TD) who are refractory or ineligible to erythropoiesis‐stimulating agents (ESAs) remain limited. Despite evidence of efficacy from clinical trials and real‐world studies, long‐term data in routine clinical practice are scarce, particularly regarding its effects on non‐erythroid lineages. Furthermore, there is currently no consensus on the total duration of treatment, especially in non‐responding cases. Thus, we analyzed 48 patients with low‐risk MDS‐RS treated with Luspa for ESA‐refractory RBC‐TD. Response was assessed at 6 months, 1 year, and 2 years according to International Working Group (IWG) 2018 criteria. At 6 months, 23/42 (54.8%) and 15/42 (35.7%) patients reached a response and transfusion independence, respectively. At 1 year, 16/30 (53.3%) patients showed a response, including 12 who already responded at 6 months. At 2 years, 10/20 (50%) patients maintained response and 2/20 (10%) were de novo responders. Treatment was well tolerated, with no significant adverse events reported; 21 (43.8%) patients discontinued Luspa, principally due to lack of response. After a median follow‐up of 29.8 months (95% CI: 24.4–35.2), 6‐month responders had longer overall survival in a landmark analysis. Exploratory analyses identified associations of 6‐month response with additional somatic mutations and the SF3B1 hotspot mutation, the latter retained in the multivariable model; monocyte count was associated with 2‐year response. Neutrophil counts significantly increased at 1 year compared with baseline, while platelet counts remained stable. Intriguingly, monocytes were increased at the three time points compared to baseline. Specifically, long‐term responders presented higher levels of neutrophils and monocytes, as well decreased level of LDH, compared with non‐responders. Responses were observed during long‐term treatment, mainly in patients who had responded at earlier assessments. Decreasing evaluable sample sizes and the retrospective design limit interpretation. Associations with survival and non‐erythroid blood counts require confirmation and should not be interpreted as causal effects.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →